| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Preclinical |
Authors' Affiliations: 1 Department of Neurosurgery, Brigham and Women's Hospital and Children's Hospital and 2 Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 3 Department of Neurosurgery, Seoul National University Hospital, Seoul, South Korea; 4 Laboratory for Cancer Drug Delivery and Mammalian Cell Technology, Technion-Israel Institute of Technology, Haifa, Israel; and 5 Division of Neurology, UBC Hospital, University of British Columbia, Vancouver, British Columbia, Canada
Requests for reprints: Rona S. Carroll, Department of Neurosurgery, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115. Phone: 671-278-0177; Fax: 617-232-9029; E-mail: rcarroll{at}rics.bwh.harvard.edu.
A unique characteristic of neural stem cells is their capacity to track glioma cells that have migrated away from the main tumor mass into the normal brain parenchyma. PEX, a naturally occurring fragment of human metalloproteinase-2, acts as an inhibitor of glioma and endothelial cell proliferation, migration, and angiogenesis. In the present study, we evaluated the antitumor activity of PEX-producing human neural stem cells against malignant glioma. The HB1.F3 cell line (immortalized human neural stem cell) was transfected by a pTracer vector with PEX. The retention of the antiproliferative activity and migratory ability of PEX-producing HB1.F3 cells (HB1.F3-PEX) was confirmed in vitro. For the in vivo studies, DiI-labeled HB1.F3-PEX cells were stereotactically injected into established glioma tumor in nude mice. Tumor size was subsequently measured by magnetic resonance imaging and at the termination of the studies by histologic analysis including tumor volume, microvessel density, proliferation, and apoptosis rate. Histologic analysis showed that DiI-labeled HB1.F3-PEX cells migrate at the tumor boundary and cause a 90% reduction of tumor volume (P < 0.03). This reduction in tumor volume in animals treated with HB1.F3-PEX was associated with a significant decrease in angiogenesis (44.8%, P < 0.03) and proliferation (23.6%, P < 0.03). These results support the use of neural stem cells as delivery vehicle for targeting therapeutic genes against human glioma.
This article has been cited by other articles:
|
|
 |
|
  S. M. Kim, J. Y. Lim, S. I. Park, C. H. Jeong, J. H. Oh, M. Jeong, W. Oh, S.-H. Park, Y.-C. Sung, and S.-S. Jeun Gene Therapy Using TRAIL-Secreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells against Intracranial Glioma Cancer Res., December 1, 2008; 68(23): 9614 - 9623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Zhao, J. Najbauer, E. Garcia, M. Z. Metz, M. Gutova, C. A. Glackin, S. U. Kim, and K. S. Aboody Neural Stem Cell Tropism to Glioma: Critical Role of Tumor Hypoxia Mol. Cancer Res., December 1, 2008; 6(12): 1819 - 1829. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Kendall, J. Najbauer, H. F. Johnston, M. Z. Metz, S. Li, M. Bowers, E. Garcia, S. U. Kim, M. E. Barish, K. S. Aboody, et al. Neural Stem Cell Targeting of Glioma Is Dependent on Phosphoinositide 3-Kinase Signaling Stem Cells, June 1, 2008; 26(6): 1575 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Duvshani-Eshet, O. Benny, A. Morgenstern, and M. Machluf Therapeutic ultrasound facilitates antiangiogenic gene delivery and inhibits prostate tumor growth Mol. Cancer Ther., August 1, 2007; 6(8): 2371 - 2382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Lee, K. S. Kim, E. J. Kim, H. B. Choi, K. H. Lee, I. H. Park, Y. Ko, S. W. Jeong, and S. U. Kim Brain Transplantation of Immortalized Human Neural Stem Cells Promotes Functional Recovery in Mouse Intracerebral Hemorrhage Stroke Model Stem Cells, May 1, 2007; 25(5): 1204 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-K. Kim, S. U. Kim, I. H. Park, J. H. Bang, K. S. Aboody, K.-C. Wang, B.-K. Cho, M. Kim, L. G. Menon, P. M. Black, et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin. Cancer Res., September 15, 2006; 12(18): 5550 - 5556. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
